UroToday - ICS 2007 ABST[89] - Transdermal Oxybutynin for Overactive Bladder: Satisfaction and Perceived Effectiveness

Home

Conference Coverage

ICS 2007 ABST[89] - Transdermal Oxybutynin for Overactive Bladder: Satisfaction and Perceived Effectiveness

Presented on August 23, 2007

Hypothesis /aims of study:
The Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin (MATRIX) study examined the safety and effectiveness of the oxybutynin transdermal system (OXY-TDS) in a community-based population of adults with overactive bladder (OAB) [1]. In this analysis, we describe participant perceptions of OXYTDS and of their OAB condition during the MATRIX study.

Study design, materials and methods:
This 6-month, open-label study at 327 US centres included individuals =18 years old with symptoms of OAB. Study participants were treated with OXY-TDS 3.9 mg/day (patch changed twice weekly). Global OAB severity was selfassessed with the Patient Perception of Bladder Condition (PPBC), which was administered at a baseline clinic visit and during monthly computer-assisted telephone interviews (CATIs) [2]. Perceptions of OXY-TDS were recorded during the same CATI calls; respondents previously treated for OAB were also asked to compare OXY-TDS with prior therapies.

The patch was considered "convenient" or "very convenient" by most respondents at month 1 (75.3%), month 3 (76.3%), and month 6 (77.9%). During daily activities, most respondents were not aware of the patch (66.0%, 64.9%, and 72.3% at months 1, 3, and 6). Among those who were aware of the patch, it rarely affected daily activities (“never” or “infrequently,” 70.1%, 60.6%, and 61.3% at months 1, 3, and 6). Compared with prior treatments for OAB, OXY-TDS was reported by most respondents to offer “some benefits” or “significant benefits” at month 1 (62.3%), month 3 (66.1%), and month 6 (69.8%) (Figure 3). Similar results were attained at months 1, 3, and 6 for ease of application (67.0%, 71.1%, and 70.3%), effectiveness (57.2%, 61.8%, and 63.0%), and ability to tolerate (60.3%, 60.8%, and 62.6%).

Interpretation of results:
Self-reported global OAB severity improved steadily during this 6-month study. Perceptions of OXY-TDS were favourable and stable during treatment. This is consistent with observed correlation between treatment satisfaction and overall perceived improvement in urinary incontinence [3].

Concluding message:
Perceived OAB severity decreased significantly during the study. Most participants were satisfied with OXY-TDS throughout the treatment period. OXY-TDS was considered superior to other therapies by most of those previously treated for OAB.

References:
[1] BJU Int (2007) 99; 836-844.
[2] Eur Urol (2006) 49; 1079-1086.
[3] Neurourol Urodyn (2006) 25; 411-417.

Authors:
Sand P, McIlwain M
Evanston Continence Center, Northwestern University, Feinberg School of Medicine, Evanston, Illinois, Watson Laboratories, Inc., Morristown, New Jersey

FUNDING: Support was provided by Watson Laboratories, Inc.
CLINICAL TRIAL REGISTRATION: OXY0402; http:/www.clinicaltrials.gov identifier NCT00224146
HUMAN SUBJECTS: This study was approved by the The protocol and supporting documents were approved by the institutional review board at each participating site. and followed the Declaration of Helsinki Informed consent was obtained from the patients.

UroToday.com Full Conference Coverage

Reader Comments

Please log-in or register in order to submit comments.

< Prev		Next >

browse categories

Member's Section

Quick Search

Featured Conference

Resources